Regulatory Affairs and Pharmacovigilance in Austria: A Practical Guide for Pharma Companies

Introduction

Austria is an established pharmaceutical market within the European Union (EU). For companies seeking to introduce or maintain medicinal products in the country, regulatory compliance involves more than obtaining marketing authorisation. Organisations must also manage product changes, monitor medicine safety and maintain accurate regulatory documentation throughout the product lifecycle.

The Austrian Federal Office for Safety in Health Care (BASG) is the national authority responsible for key aspects of medicinal product authorisation and safety oversight. Its work operates within the wider EU regulatory framework, including European Medicines Agency (EMA) procedures and Good Pharmacovigilance Practices (GVP).

Understanding how national and EU requirements interact helps pharmaceutical companies plan submissions, allocate responsibilities and maintain compliance after approval.

1. Austria’s Pharmaceutical Regulatory Framework

BASG oversees important regulatory activities for medicinal products in Austria. During authorisation, the authority evaluates whether a medicine meets applicable quality, safety and efficacy requirements. The Austrian Medicines Act (Arzneimittelgesetz, AMG), together with relevant EU legislation, provides the legal foundation for these activities.

Companies should understand which procedure applies to their product and intended markets. The main EU authorisation routes include:

• National procedure: Authorisation for the Austrian market through the national authority.
• Mutual recognition procedure (MRP): Extends an existing national authorisation to additional EU Member States.
• Decentralised procedure (DCP): Supports simultaneous applications in multiple Member States when the medicine has not yet received an EU national authorisation.
• Centralised procedure: Provides a single EU-wide authorisation following EMA assessment and European Commission decision-making.

The appropriate route depends on the product, its regulatory eligibility and the company’s market access strategy. Organisations planning local submissions can review Regulatory Services in Austria when assessing country-specific regulatory activities.

2. Marketing Authorisation Pathways

A marketing authorisation application (MAA) must present sufficient evidence to demonstrate that a medicinal product meets regulatory standards. The Common Technical Document (CTD) provides the harmonised dossier structure used across many EU procedures.

Its five modules cover:

• Module 1: Regional administrative and product information.
• Module 2: Quality, non-clinical and clinical summaries.
• Module 3: Quality, manufacturing and control information.
• Module 4: Non-clinical study reports.
• Module 5: Clinical study reports.

Submission quality depends on the accuracy, consistency and completeness of the dossier. Companies should check that manufacturing details, product information and supporting evidence remain aligned across relevant documents.

BASG also highlights the importance of lifecycle planning. Changes to an authorised medicine may require regulatory submissions, and the appropriate procedure depends on the nature of the change. Companies should therefore establish change-control processes before issues arise.

3. Pharmacovigilance Obligations in Austria

Pharmacovigilance continues throughout a medicine’s lifecycle. Marketing authorisation holders (MAHs) must operate a functioning system to collect, assess and report suspected adverse reactions and identify changes in a product’s benefit-risk balance.

In Austria, these responsibilities are governed by the AMG and applicable EU pharmacovigilance legislation. Key activities include:

• Maintaining a pharmacovigilance system master file (PSMF).
• Having continuous access to a suitably qualified EU qualified person responsible for pharmacovigilance (QPPV).
• Collecting and processing suspected adverse reaction reports.
• Submitting applicable individual case safety reports through EudraVigilance.
• Preparing periodic safety update reports (PSURs) when required.
• Maintaining and updating risk management plans (RMPs).
• Monitoring safety signals and the effectiveness of risk-minimisation measures.

BASG explains that PSUR requirements depend on factors such as the active substance, EURD list, authorisation type and conditions in the marketing authorisation. Companies should not assume that every product follows the same submission schedule.

BASG and AGES also conduct pharmacovigilance inspections to assess whether MAHs have suitable facilities, processes and competencies. Organisations can explore Pharmacovigilance Services in Austria when reviewing local safety-monitoring responsibilities and system requirements.

4. Post-Authorisation and Regulatory Documentation

Regulatory work continues after a product enters the market. Changes to manufacturing sites, specifications, processes, product information or safety data may require assessment and, where applicable, notification or approval.

A structured lifecycle process should include:

• Identifying proposed changes and assessing their regulatory impact.
• Determining the applicable variation or notification route.
• Preparing supporting data and updated dossier documents.
• Tracking submission milestones and authority responses.
• Implementing approved changes through controlled procedures.

Product information must also remain consistent with approved conditions and emerging safety requirements. This includes the Summary of Product Characteristics (SmPC), package leaflet and labelling.

Companies should maintain clear document ownership, version control and traceable approval records. These controls help prevent discrepancies between regulatory submissions, manufacturing documentation and information supplied to healthcare professionals.

5. Building a Sustainable Compliance Strategy

A reliable compliance programme connects regulatory affairs, quality assurance, medical and pharmacovigilance teams. It should also account for the company’s product portfolio, authorisation routes and operating model.

Practical measures include:

• Monitor regulatory developments: Track relevant BASG, EMA and European Commission updates.
• Assess compliance gaps: Compare current procedures and documentation against applicable requirements. A structured Regulatory Gap Analysis can help identify areas requiring corrective action.
• Plan regulatory activities early: Define submission pathways, evidence requirements and responsibilities before key milestones.
• Maintain inspection readiness: Keep procedures, training records, safety documentation and vendor oversight evidence current.
• Review strategic priorities: Use Regulatory Strategy Services to inform decisions about market entry, submission planning and lifecycle changes.

BASG notes that registration in EMA’s IRIS platform has been mandatory since January 2025 for lifecycle procedures managed by EMA. This can also affect nationally or decentrally authorised products involved in certain EU procedures. Companies should therefore consider platform access as part of their regulatory readiness.

Conclusion

Regulatory affairs and pharmacovigilance in Austria require coordinated oversight of authorisation procedures, dossier quality, post-approval changes and medicine safety. Companies must understand BASG expectations while keeping pace with the broader EU framework.

By maintaining accurate documentation, effective safety systems and a proactive approach to regulatory change, pharmaceutical organisations can support continued compliance and protect patients throughout the product lifecycle.

Why Choose DDReg as your Consulting Partner

For broader regulatory planning, Life Science Consulting Services can help readers explore regulatory topics across the life sciences sector. Organisations monitoring changing requirements may also review Regulatory Intelligence Tools, while Regulatory Affairs Lifecycle Management provides a further resource for understanding how regulatory activities can be coordinated over time.